These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 2544128)
1. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Fareed J; Walenga JM; Hoppensteadt D; Huan X; Nonn R Ann N Y Acad Sci; 1989; 556():333-53. PubMed ID: 2544128 [TBL] [Abstract][Full Text] [Related]
2. Comparative human pharmacology of low molecular weight heparins. Harenberg J; Stehle G; Augustin J; Zimmermann R Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502 [TBL] [Abstract][Full Text] [Related]
3. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Fareed J; Walenga JM; Hoppensteadt D; Huan X; Racanelli A Haemostasis; 1988; 18 Suppl 3():3-15. PubMed ID: 2840372 [TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization. Barrowcliffe TW; Thomas DP Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459 [TBL] [Abstract][Full Text] [Related]
5. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Fareed J; Walenga JM; Racanelli A; Hoppensteadt D; Huan X; Messmore HL Haemostasis; 1988; 18 Suppl 3():33-47. PubMed ID: 2840373 [TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Cziraky MJ; Spinler SA Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology and special clinical applications of low-molecular-weight heparins. Harenberg J; Heene DL Am J Hematol; 1988 Dec; 29(4):233-40. PubMed ID: 3055954 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Padilla A; Gray E; Pepper DS; Barrowcliffe TW Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921 [TBL] [Abstract][Full Text] [Related]
9. In vitro and ex vivo activities of CY216: comparison with other low molecular weight heparins. Ofosu FA Haemostasis; 1990; 20 Suppl 1():180-92. PubMed ID: 1964661 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the biological effects of low-molecular-weight heparins. Bender N; Seidl C; Weichert W; Breddin HK Haemostasis; 1988; 18 Suppl 3():23-32. PubMed ID: 2840371 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of low molecular weight heparins: knowledge to date and their application to therapy. Hull RD; Pineo GF Semin Thromb Hemost; 1994; 20(4):339-44. PubMed ID: 7899865 [TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins and their use in obstetrics and gynecology. Fejgin MD; Lourwood DL Obstet Gynecol Surv; 1994 Jun; 49(6):424-31. PubMed ID: 8090379 [TBL] [Abstract][Full Text] [Related]
18. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Brieger D; Dawes J Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of low molecular weight heparins. Bara L; Samama M Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460 [TBL] [Abstract][Full Text] [Related]
20. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]